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The relaxed complex scheme, a virtual-screening
methodology that accounts for protein receptor
flexibility, was used to identify a low-micromolar,
non-bisphosphonate inhibitor of farnesyl diphosphate
synthase. Serendipitously, we also found that several
predicted farnesyl diphosphate synthase inhibitors
were low-micromolar inhibitors of undecaprenyl
diphosphate synthase. These results are of interest
because farnesyl diphosphate synthase inhibitors
are being pursued as both anti-infective and antican-
cer agents, and undecaprenyl diphosphate synthase
inhibitors are antibacterial drug leads.
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Over 55 000 naturally occurring isoprenoids have been identified
(1). These compounds, the products of the mevalonate, non-mevalo-
nate, and isoprenoid biosynthesis pathways, have diverse functions
including visual pigmentation, endocrine signaling, signal transduc-
tion, and cell membrane ⁄ cell wall biosynthesis (2). Owing to the
diversity of isoprenoid products, isoprenoid biosynthesis is the tar-
get of several FDA-approved drugs, including treatments for high
cholesterol (statins), cancer (taxol), and bone diseases (bisphospho-
nates) (3). Inhibitors of the isoprenoid biosynthesis pathways are
also effective against trypanosomes, including Trypanosoma cruzi,
the organism responsible for Chagas' disease, and Trypanosoma
brucei, the organism responsible for human African sleeping sick-
ness (4–16), as well as against bacteria such as drug-resistant
Staphylococcus aureus, an ever increasing public-health threat (17).
Two interesting new anti-infective targets involved in isoprenoid
biosynthesis are farnesyl diphosphate synthase (FPPS) and undeca-
prenyl diphosphate synthase (UPPS) (18–21). FPPS catalyzes the
condensation of dimethylallyl diphosphate (DMAPP) with isopentenyl
diphosphate (IPP) to form geranyl diphosphate (GPP) and thence,
farnesyl diphosphate (FPP) (22), while UPPS elongates FPP via cis
double-bond addition to produce undecaprenyl diphosphate (UPP)
(Figure 1) (19). Both enzymes are essential for bacterial cell growth,
and UPPS is of particular interest because it is absent in humans.
Here, we first describe a virtual-screening approach used to identify
novel, non-bisphosphonate FPPS inhibitors, thought to be less vul-
nerable to rapid removal from the circulatory system via bone min-
eral binding than their bisphosphonate counterparts. Next, we show
that these compounds also inhibit two bacterial UPPS enzymes,
suggesting a new route to polypharmacophoric, combined
FPPS ⁄UPPS inhibition.
Methods and Materials
Molecular dynamics (MD) methodology
The initial model for an MD simulation of FPPS was derived from
chain A of a T. brucei FPPS structure (PDB ID: 2EWG) (22). To calcu-
late the partial charges of the minodronate ligand, Gaussian 03
revision B.04 (Gaussian, Inc.) was used to first minimize the ligand
coordinates (6-31G* basis set). A grid potential was then calculated
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from the resulting structure. The grid potential was subsequently
processed with the RESP program (Amber 4.1) for a restrained
charge fitting. Antechamber was used to generate additional ligand
parameters. To maintain the coordination of the Mg2+ with the
ligand phosphate groups, as well as to maintain the protein–
ligand–Mg2+ charge interaction, distances between a number of
atom pairs were restrained to the crystallographic values using a
force constant of 50 kcal ⁄2 (Figure S1).
The protein was geometry optimized for 2000 steps in vacuo by
applying 250 steps of steepest descent, followed by 1750 steps of
conjugate gradient, with SANDER (23). The protein active-site Mg2+
and ligand were then loaded into Xleap (23) with the ff99SB force
field, and the system was solvated and neutralized. The resulting
system contained 20 481 water molecules and 13 Na+. A two-step
minimization (500 steps of steepest descent, followed by 1500
steps of conjugate gradient) was then used to relax the system,
first with the protein restrained (force constant 200 kcal ⁄2) and
then with all atoms free. This minimization was followed by 50 ps
of NPT simulation with protein restrained (force constant
200 kcal ⁄2) to equilibrate the solvent, followed by another
100 ps of NPT simulation with the protein free to adjust the system
density.
The production run was executed under the NVT ensemble at
300 K. Periodic boundary conditions were used. The cutoff for the
non-bonded interactions was 8 , and the cutoff for the non-
bonded list update was 10 . The SHAKE (24) algorithm was used
to constrain bonds with hydrogen atoms. A time step of 2 fs was
selected. The production simulation ran for 40 ns.
Clustering
From the last 32 ns of the MD simulation, 1601 frames at regularly
spaced intervals were extracted. These frames were aligned by the
protein Ca atoms and clustered by root mean square deviation
(RMSD) conformational clustering using GROMOS++ (25). The hydro-
gen bond networks of the members of the three most populated
clusters were subsequently inspected to verify that each cluster
was structurally distinct. The set of the central members of each
cluster constituted an 'ensemble' of protein conformations, repre-
sentative of the many conformations sampled during the MD simu-
lation.
Virtual-screening protocol
The FPPS crystal-structure used for docking was prepared from
2EWG (22), a structure deposited in the RCSB Protein Data Bank
(26). Hydrogen atoms were added to chain A and associated water
molecules using the PDB2PQR server (27,28). Other FPPS protein
structures were extracted from the MD simulation described earlier.
The UPPS structure was obtained from an MD simulation that has
been described previously (29).
The receptor structures were processed with the AutoDockTools
(ADT) (30) receptor preparation script, which also computed Gastei-
ger charges. The FPPS partial charges of the active-site Mg2+ were
ultimately set to +1.5 e for docking and to 0.0 e for subsequent re-
scoring. The FPPS and UPPS affinity-map grids were 37.50 
· 41.25  · 37.50  and 40.125  · 40.125  · 40.125 , respec-
tively. Both were centered on their respective active sites and had
0.375  spacing. For each protein receptor, the appropriate affinity
maps were calculated to accommodate the atom types of all library
ligands.
Ligands were processed with ADT to add missing hydrogen atoms,
to compute Gasteiger partial charges for each atom and to merge
non-polar hydrogen atoms. For some compounds, hydrogen atoms
were added or removed as needed by Discovery Studio (Accelrys) or
Maestro (Schrodinger), followed by a geometry optimization. All tor-
sion angles were assigned with AutoTors (31), enabling full-ligand
flexibility.
To identify AutoDock parameters best suited for FPPS, we
first selected four known inhibitors: minodronate (1), [1-phospho-
no-2-(pyridin-2-ylamino)ethyl]phosphonic acid (2), [2-(dimethyl-
lambda4-sulfanyl)-1-hydroxyethane-1,1-diyl]bis(phosphonic acid)
(3), and [1-hydroxy-3-(methyl-(4-phenylbutyl)amino)-1-phosphono-pro-
pyl]phosphonic acid (4) (Table 1). Both the AutoDock parameters
as well as the partial charges assigned to the active-site Mg2+
were varied systematically, and the known inhibitors were docked
into their respective FPPS crystal structures (PDB codes: 2EWG,
2I19, and 2P1C). A parameter set was identified that could
recapture the crystallographic poses of 1, 2, 3, and 4, with
RMSD values of 0.81, 1.98, 1.26, and 3.20 , respectively. The
docking of 4 was the least accurate, perhaps because 4 has
many rotatable bonds and interacts with the protein largely
through non-specific hydrophobic contacts. Nevertheless, visual
inspection revealed that 4 occupied the correct geometric
space, and the nitrogen atom and phenyl ring were correctly
positioned.
The following docking parameters were ultimately selected: popu-
lation size of 250, 15 · 106 evaluations, 2.7 · 104 generations,
and 100 runs. Clustering of the predicted poses was performed
with a cutoff of 0.5  RMSD. Default values were used for the
remaining docking parameters. For consistency, these same param-
eters were used in UPPS docking. For FPPS, the best predicted
Figure 1: Selected steps in the
isoprenoid biosynthetic pathway.
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binding pose was judged to be that corresponding to the lowest-
energy AutoDock cluster. For UPPS, the lowest-energy pose
located in a region of known pharmacological significance was
selected.
FPPS ensemble–based compound scoring
Weighted ensemble-average scores for each compound docked into
FPPS were calculated according to equation 1:
E ¼
P23
i¼1
wiEi
P23
i¼1
wi
where E is the weighted ensemble-average score, wi is the size of
cluster i, and Ei is the AutoDock score of the compound docked into
the centroid of cluster i.
1 2 3 
4 5 6 
7 8 9
10 11 12
13 14 15
16 17 18
19 20 21 
22
Table 1: Positive controls used in the virtual screens (compounds 1–4) and the compounds tested experimentally against farnesyl diphos-
phate synthase and undecaprenyl diphosphate synthase (compounds 5–22)
Inhibitors of Isoprenoid Biosynthesis
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Cloning, expression, and purification of FPPS
and UPPS from S. aureus
The genes encoding FPPS and UPPS were amplified from S. aureus
Mu3 genome DNAs using a polymerase chain reaction (PCR). For
FPPS, 5¢GAC GAC GAC AAG ATG ACG AAT CTA CCG TAC 3¢ was
used as the forward primer and 5¢GAG GAG AAG CCC GGT TAG
TGA TCC CTG C 3¢ as the reverse primer. For UPPS, the forward pri-
mer was 5¢GAC GAC GAC AAG ATG TTT AAA AAG CTA ATA AAT
AAA AAG AAC AC 3¢, and the reverse primer was 5¢GAG GAG AAG
CCC GGC TAC TCC TCA CTC3¢. The amplified FPPS and UPPS genes
were purified and ligated into pET-46 Xa ⁄ LIC and pET-41 Xa ⁄ LIC
vectors (Novagen, Madison, WI, USA), respectively. The plasmid
with the correct FPPS or UPPS gene was subsequently expressed in
Escherichia coli BL21 (DE-3) (Novagen). Following cell harvest and
lysis, the (His)6 tagged FPPS protein was purified by using a HiTrap
chelating HP column (GE Healthcare, Piscataway, NJ, USA) and
judged by SDS–PAGE to be highly pure. A GSTrap FF column (GE
Healthcare) was used to purify the GST-fused UPPS. The fusion tag
was then removed by recombinant enterokinase (EMD CROP BIOSCI-
ENCE, INC., Brookfield, WI, USA), and the tag-removed protein was
obtained by passing the sample through the same GSTrap FF col-
umn. The protein was highly pure according to Coomassie blue–
stained SDS–PAGE.
Assay methodology
The initial screening of FPPS inhibitors obtained from the National
Cancer Institute or purchased from Hit2Lead (Chembridge Corpora-
tion, San Diego, CA, USA) was carried out using a rapid continu-
ous spectrophotometric assay (32) on 96-well plates with 200 lL
reaction mixture (50 mM Tris ⁄HCl, 1 mM MgCl2, at pH 7.4, 200 pg
FPPS, 200 lM IPP, and 200 lM GPP) in each well. Since there is
always the possibility that there could be false positives because
of inhibition of the coupling enzymes used in this assay, accurate
IC50 values were then determined for the initial hits by using a
radiometric assay. Briefly, various amounts of potential inhibitor
were pre-incubated with FPPS enzymes in a buffer containing
50 mM Hepes, 5 mM MgCl2, and 18 lM FPP at pH 7.4. After
15 min, radio-labeled IPP was added, and the reaction was
allowed to proceed for 20 min at 37 C. Reactions were quenched
by the addition of 150 lL of HCl ⁄MeOH and incubated at 37 C
for 20 min to hydrolyze the allylic diphosphates. The reaction mix-
tures were neutralized by the addition of 75 lL of 6 N NaOH and
then extracted with 500 lL of hexane. Two hundred microliters of
the organic phase was transferred to a scintillation vial for count-
ing. The IC50 and Ki values were obtained by fitting the data to a
standard rectangular hyperbolic dose–response function in Origin
6.1a). To prevent aggregate-based inhibition, 2 mg ⁄mL BSA was
included in the reaction mixture, and all reactions were carried out
in duplicate.
Activity in UPPS inhibition was again initially screened using a rapid
spectrophotometric assay (33). Accurate IC50 values for the hits
were then determined by radiometric assay, as described previously
(33). Briefly, these assays were carried out in duplicate in a buffer
containing 50 mM Tris ⁄HCl, 1 mM MgCl2, 2.5 lM FPP, and 25 lM
radio-labeled IPP at pH 7.4. After 30 min incubation at 25 C, the
reaction was terminated by adding 200 lL of 0.5 M EDTA, and the
reaction product was extracted with 500 lL butanol. 300 lL of the
organic (upper) layer was then mixed with 3 mL scintillation cocktail
and counted for 1 min in a scintillation counter. IC50 values were
obtained by fitting the inhibition data to a standard rectangular
hyperbolic dose–response function in Origin 6.1a. Binding to E. coli,
UPPS was retested in the presence of 0.1% Triton-X-100,
0.1 mg ⁄mL BSA, and 2 mg ⁄mL BSA to rule out aggregation-based
inhibition.
The identities of compounds 5–8 (Table 1) were confirmed by mass
spectrometry, supporting the conclusion that these compounds are
in fact responsible for enzyme inhibition.
Results and Discussion
The current study describes a virtual-screening approach used to
identify novel, non-bisphosphonate FPPS inhibitors. The identified
compounds also inhibit two bacterial UPPS enzymes, suggesting a
new route to polypharmacophoric, combined FPPS ⁄UPPS inhibition.
Molecular dynamics (MD) simulations
As the molecular motions of protein receptors play a critical role in
ligand binding, we first studied FPPS dynamics before attempting to
computationally identify non-bisphosphonate FPPS inhibitors. When
a ligand approaches its receptor, it does not encounter a single sta-
tic structure, but rather an ensemble of structures, both open and
closed. Upon ligand binding, the closed conformations are stabi-
lized, and the population of configurations shifts to accommodate
the ligand. Additionally, ligand binding may induce new protein con-
formations, not sampled in the ligand-free (apo) state, that facilitate
improved protein–ligand interactions (34).
To study protein flexibility, we performed a 40-ns FPPS MD simula-
tion. The protein conformations sampled during the last 32 ns were
subsequently clustered into 23 groups by RMSD conformational
clustering. A set of 23 protein conformations (an 'ensemble'), com-
posed of the centroid members of each cluster, was taken to be
representative of all conformations sampled. Figure 2 shows these
23 clusters superimposed, demonstrating that the FPPS active site
is highly flexible.
Virtual screening
Past experience has demonstrated that in the case of flexible pro-
teins, accounting for molecular motions is important for predicting
ligand binding (35–38). To build upon the protein-flexibility informa-
tion obtained from the MD simulations, we used the computer pro-
gram AutoDock 4 (31) to dock the 2000 compounds in the
National Cancer Institute (NCI) Diversity Set I into various FPPS con-
formations. Since it was computationally intractable to dock all of
these compounds into all 23 protein conformations of the MD
ensemble, we instead performed four screens by docking into a rep-
resentative FPPS crystal structure (T. brucei FPPS; PDB ID: 2EWG;
(22)) and the top three ensemble conformations, representing 73.1%
of the 32-ns MD trajectory. The top 20 ligands from each of the
four virtual screens were then compiled into a single list of 73
unique, predicted FPPS inhibitors.
Durrant et al.
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AutoDock 4 (31) was used for ligand docking because it combines a
well-tested, physics-based scoring function with a Lamarckian
genetic algorithm to improve accuracy (31,39). Although less accu-
rate than thermodynamic integration (31,40), single-step perturba-
tion (41), and free energy perturbation (42), AutoDock provides more
rapid estimates of binding energies and performs favorably when
compared with other docking programs (43) such as DOCK (44), FleX
(45), and GOLD (46).
To further account for protein flexibility, we next used the relaxed
complex scheme (RCS) (47), a computational method that combines
MD simulations and computer docking, to rerank the 73 candidate
inhibitors identified in the preliminary screens. These compounds
were docked into the 23 protein conformations extracted from the
FPPS MD simulation and then ranked by their ensemble-average
docking scores, rather than the docking score associated with a sin-
gle (e.g., X-ray) structure alone. While the RCS is more computa-
tionally intensive than traditional virtual screens, compound ranking
is potentially improved. The RCS approach has been used previously
to successfully identify several enzyme inhibitors, including inhibi-
tors of FKBP (35), HIV integrase (36), T. brucei RNA editing ligase 1
(37), and TbGalE (38).
To expand the list of potential inhibitors, we next considered
additional compounds similar to the top 20 of the 73 NCI com-
pounds identified via RCS docking. Searches of online databases
identified 228 similar compounds from the Hit2Lead database
(Chembridge) and 207 additional compounds from the NCI. These
compounds were docked as described earlier, again into the top
three protein conformations from the MD ensemble and the repre-
sentative FPPS crystal structure. The top 40 compounds from each
of these four screens were then compiled into a single list of 71
unique compounds that were reranked using the RCS described
above. Additionally, four positive controls (compounds 1–4,
Table 1) were included in the RCS screen. Thus, a total of 148
compounds were scored with the RCS (73 from the NCI Diversity
Set I, 71 from the library of similar compounds, and four positive
controls).
The FPPS active site contains three Mg2+, and AutoDock is known
to overestimate binding energies when docking negatively charged
ligands into active sites with metal cations (48). In the current
study, the active-site Mg2+ were initially assigned partial charges of
+1.5 e because this charge was required to recapture the crystallo-
graphic poses of the four positive controls (minodronate, 1, and
2–4, Table 1). Despite the inaccuracies in the predicted binding
energies that likely result from using this partial charge, all four
positive controls still ranked in the top 25% of the 148 candidate
FPPS inhibitors.
Since overestimating the electrostatic interaction energies might
mask the energies of other interactions, we next set the partial
charges of the active-site Mg2+ to 0.0 e and rescored all 148 com-
pounds with the AutoDock scoring function, without redocking. The
ensemble-average (RCS) score of the best compound after rescoring
was reasonable ()10.9 kcal ⁄mol); however, the positive controls no
longer ranked well. To strike a balance, we reranked the 148 com-
pounds again using the average of the scores obtained when the
active-site Mg2+ had charges of 0.0 e and +1.5 e. The top 10 com-
pounds from each of these three rerankings were compiled into a
single list of 18 unique predicted lead compounds (compounds 5–
22, Table 1).
Experimental screening of FPPS and UPPS
inhibition
We first tested compounds 5–22 for inhibition of T. brucei (20) and
S. aureus FPPS. As a counter screen, we also screened for human
FPPS inhibition (Table 2). Representative dose–response curves are
shown in Figure 3. FPPS inhibition was seen with 5, (Z)-1,2-bis(4-
sulfonaphthalene-2-yl)diazene oxide (T. brucei FPPS IC50 = 20.8 lM,
Ki = 10 lM; human FPPS IC50 = 237 lM, Ki = 22 lM).
The best predicted pose of 5 bound to FPPS + Mg2+ is shown in
Figure 4A. Two sulfonate groups are predicted to interact with the
three active-site Mg2+, similar to the pose adopted by the two
Figure 2: Twenty-three representative protein conformations
extracted from an molecular dynamics simulation of farnesyl diphos-
phate synthase suggest significant active-site flexibility. The protein
is shown in ribbon, the ligand is shown in thick licorice, selected
active-site residues are shown in thin licorice, and the active-site
Mg2+ cations are shown as green spheres.
Table 2: Farnesyl diphosphate synthase (FPPS) and undecaprenyl
diphosphate synthase (UPPS) inhibition by 5–8
HsFPPS
IC50 (lM)
TbFPPS
IC50 (lM)
SaFPPS
IC50 (lM)
EcUPPS
IC50 (lM)
SaUPPS
IC50 (lM)
5 237 20.8 46.3 5.7 6.7
6 >300 >300 >300 3.2 6.9
7 >300 >300 >300 37 16
8 >300 >300 >300 42 12
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phosphonate groups of known bisphosphonate FPPS inhibitors
(22,49–54). Additionally, the oxygen atom of the diazene oxide lin-
ker is predicted to form a hydrogen bond with the T213 side chain
hydroxyl group. This hydrogen bond is likely strong, because the for-
mal charge on the diazene oxide oxygen atom is )1. Finally, there
may be p–cation interactions between one of the naphthalene
groups of compound 5 and the positively charged K212 side chain.
As the computational docking results indicated that 5 bound to the
allylic binding site of FPPS, it seemed possible that it might also
bind to the allylic site of the C55 prenyl synthase UPPS, which uti-
lizes FPP as a substrate. To investigate this possibility, 5–22 were
tested for inhibition of UPPS from S. aureus and E. coli (Table 2).
Several of the predicted FPPS inhibitors did in fact inhibit UPPS.
The most potent compound, 6, had an IC50 value of 3.2 lM
(Ki = 0.4 lM) against S. aureus UPPS, but no measurable activity
(IC50 > 300 lM) against human FPPS (Table 2).
A UPPS conformation extracted from a recent MD simulation (29)
was then used to better understand the binding of 5. Compound 5
was docked into the protein conformation with the largest pocket
volume because that conformation has been shown to yield the
best correlations between activity and docking score (29). The high-
est-scoring docked pose that placed the ligand within a region of
known pharmacological significance is shown in Figure 4B. The two
sulfonate groups of compound 5 are predicted to intercalate
between three positively charged residues, H43, R39, and K33.
Although distant in this particular conformation, perhaps because
the original MD simulation did not include a bound ligand, R77 may
also participate in ligand binding. Additionally, one of the sulfonate
groups of compound 5 is predicted to form a hydrogen bond with
N228 (not shown in Figure 4B, for clarity).
A crystallographic bisphosphonate ligand (BPH-608, PDB ID: 2E99)
(33) and sulfate ion (PDB ID: 1F75) (2) are also shown in Figure 4B
to provide further insight into the predicted binding mode of com-
pound 5. We note that one of the negatively charged sulfonate
groups of compound 5 is near the location where the phosphate
groups of known bisphosphonate inhibitors are positioned. Addition-
ally, one of the naphthalene moieties of compound 5 extends in
the same direction as the hydrophobic, aromatic rings characteristic
of recently identified bisphosphonate inhibitors (33). A crystallo-
graphic sulfate ion is positioned near the predicted location of the
diazene oxide moiety of compound 5. Both have electronegative
oxygen atoms at the same location, suggesting that this region of
the UPPS active site may be well suited to this atom type.
Conclusions and Future Directions
Compounds 5 through 8 represent interesting leads; all have
between 20 and 70 atoms (55) and possess no chiral centers, and
all but compound 8 satisfy Lipinski's rule of five (56). The polar ⁄ ch-
arged moieties so common in these compounds, thought to be
critical for metal binding, may appear at first glance to be unchar-
acteristic of actual drugs, but the predicted LogP values suggest
that only compound 8 has a partition coefficient that is atypical of
drug-like molecules (55). The hydrophobic aromatic rings of these
compounds may counterbalance any hydrophilic effect, permitting
cell membrane permeation. Additionally, there is some precedence
for doubly charged inhibitors with intracellular targets; for example,
A
B
C
Figure 3: Inhibition of farnesyl diphosphate synthase (FPPS) and
undecaprenyl diphosphate synthase (UPPS). (A) Human, Trypanosoma
brucei, and Staphylococcus aureus FPPS inhibition by 5. (B) Escheri-
chia coli and S. aureus UPPS inhibition by 5. (C) As (B) but inhibi-
tion by 6.
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methotrexate, a common cancer drug, contains two carboxylate
groups, and a recently discovered trypanocidal compound is doubly
sulfonated (57). The chief class of known FPPS inhibitors, bis-
phosphonates, are also doubly charged.
Compound 5, active against both FPPS and UPPS, is particularly
interesting. It is remarkable that one compound could inhibit two
proteins in the same pathway, especially given that FPPS and UPPS
share little sequence or structural homology. These two proteins
have only 5% sequence similarity according to ClustalW (58) and
are not structurally similar according to the FATCAT algorithm
(p = 0.0620) (59). The CATH classification (60) of UPPS and FPPS
likewise suggests that they are not closely related; UPPS belongs
to the 'alpha beta' class and has a 3-layer(aba) sandwich architec-
ture, while FPPS belongs to the 'mainly alpha' class and has an
orthogonal bundle architecture.
Although compound 5 is promising, further lead optimization is
clearly needed because the activity of 5 falls far short of the most
potent commercially available FPPS inhibitor, zoledronate. Azoxy-
benzenes and azobenzenes are not particularly drug like, except
arguably as prodrugs (e.g., Prontosil), but the diazene oxide linker
might be replaced with a sulfonate bridge or, potentially, a ketone
or ester linking group.
On the other hand, compound 6 shows promising low lM inhibition
of UPPS, but poor FPPS inhibition. This is, of course, of interest
from the perspective of anti-infective development, because selec-
tive activity against bacterial UPPS combined with poor human FPPS
inhibition may result in low human toxicity. Compound 6 is not as
potent as tetramic and tetronic acid inhibitors of Streptococcus
pneumoniae UPPS (IC50  60–120 nM) (19), although as there has
been no optimization of 6, a more appropriate comparison may be
the mean of the IC50 values reported previously, 7 lM (19).
Indeed, the first tetramic acid identified as a UPPS inhibitor (from
an experimental high throughput screening study) had an IC50 value
of 19 lM, so the 3.2 lM IC50 value for 6 against E. coli UPPS iden-
tified from our in silico HTS represents a promising lead.
The discovery of low lM, non-bisphosphonate UPPS and FPPS inhib-
itors is clearly of interest because non-bisphosphonate inhibitors
are less vulnerable to rapid removal from the circulatory system by
binding to bone mineral, as noted by Jahnke et al. (61). Addition-
ally, dual-activity FPPS ⁄GGPPS inhibitors with synergistic activity
that allows for a polypharmacophoric, multiprenyl-synthase
approach to isoprenoid biosynthesis inhibition have already been
designed (52). The current work suggests that a similar approach
may be possible for FPPS ⁄UPPS inhibition as well.
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